Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Apremilast. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B known ✓ | Q07343 | 20/20 | 1.00 |
| ▸ | PDE4C known ✓ | Q08493 | 19/20 | 1.00 |
| ▸ | PDE4A known ✓ | P27815 | 13/20 | 1.00 |
| ▸ | PDE4D known ✓ | Q08499 | 13/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apremilast SCHEMBL302671 | 1.00 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Apremilast SCHEMBL29393225 | 1.00 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Apremilast SCHEMBL29446192 | 1.00 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Apremilast SCHEMBL29392757 | 1.00 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Apremilast SCHEMBL29350625 | 1.00 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Apremilast SCHEMBL3135372 | 1.00 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Apremilast SCHEMBL15869338 | 1.00 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Apremilast SCHEMBL7135116 | 1.00 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Apremilast SCHEMBL15869341 | 1.00 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Apremilast SCHEMBL25247853 | 0.99 | PDE4B (0.98) | PDE4BPDE4CPDE4APDE4DHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 837 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250235450-A1 | COMBINATION THERAPIES COMPRISING APREMILAST AND TYK2 INHIBITORS | CELGENE CORPORATION | 2025-07-24 | — | — | US | claimed |
| US-20220339151-A1 | COMBINATION THERAPIES COMPRISING APREMILAST AND TYK2 INHIBITORS | CELGENE CORPORATION | 2022-10-27 | — | — | US | claimed |
| US-11357775-B2 | Combination therapies comprising apremilast and Tyk2 inhibitors | CELGENE CORPORATION (US) | 2022-06-14 | — | — | US | claimed |
| CN-114269336-A | Combination therapy comprising apremilast and a TYK2 inhibitor | 细胞基因公司 | 2022-04-01 | — | — | CN | claimed |
| CN-114206333-A | Combination therapy comprising apremilast and a TYK2 inhibitor | 细胞基因公司 | 2022-03-18 | — | — | CN | claimed |
| US-10919855-B2 | Process to prepare n-[2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulphonyl) ethyl]-1, 3-dioxo-2,3-dihydro-1h-isoindol-4yl]acetamide | UNICHEM LABORATORIES LTD (IN) | 2021-02-16 | — | — | US | claimed |
| US-10913717-B2 | Solid state forms of N-[2-[(I S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methyl sulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-L H-isoindol-4-yl]acetamide and process for preparation thereof | MSN LABORATORIES PRIVATE LIMITED (IN) | 2021-02-09 | — | — | US | claimed |
| US-20200345731-A1 | COMBINATION THERAPIES COMPRISING APREMILAST AND TYK2 INHIBITORS | CELGENE CORPORATION | 2020-11-05 | — | — | US | claimed |
| WO-2020222773-A1 | COMBINATION THERAPIES COMPRISING APREMILAST AND TYK2 INHIBITORS | CELGENE CORPORATION (US) | 2020-11-05 | — | — | WO | claimed |
| CN-111821297-A | Use of isoindoline derivatives for the treatment of immunoglobulin E (IgE) -mediated diseases | 天津合美医药科技有限公司 | 2020-10-27 | — | — | CN | claimed |
| WO-2017196192-A1 | CRYSTALLINE FORMS OF APREMILAST | ZAKLADY FARMACEUTYCZNE POLPHARMA SA (PL) | 2017-11-16 | — | — | WO | claimed |
| US-20170231931-A1 | PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2017-08-17 | — | — | US | claimed |
| WO-2017046319-A1 | A SYNTHETIC PATHWAY TOWARDS APREMILAST | LEK PHARMACEUTICALS D.D. (SI) | 2017-03-23 | — | — | WO | claimed |
| EP-3144393-A1 | A SYNTHETIC PATHWAY TOWARDS APREMILAST | LEK Pharmaceuticals d.d. (SI) | 2017-03-22 | — | — | EP | claimed |
| WO-2017033206-A2 | SOLID STATE FORMS OF N-[2-[(1 S)-1 -(3-ETHOXY-4-METHOXYPHENYL)-2-(METHYL SULFONYL)ETHYL]-2,3-DIHYDRO-1,3-DIOXO-L H-ISOINDOL-4-YL]ACETAMIDE AND PROCESS FOR PREPARATION THEREOF | MSN LABORATORIES PRIVATE LIMITED (IN) | 2017-03-02 | — | — | WO | claimed |
| EP-3034496-A1 | NOVEL SOLVATES OF N-[2-[(1S)-1-(3-ETHOXY-4-METHOXYPHENYL)-2-(METHYLSULFONYL)ETHYL]-2,3-DIHYDRO-1,3-DIOXO-1H-ISOINDOL-4-YL]ACETAMIDE | LEK Pharmaceuticals d.d. (SI) | 2016-06-22 | — | — | EP | claimed |
| EP-2583098-A1 | BIOMARKERS FOR THE TREATMENT OF PSORIASIS | CELGENE CORPORATION (US) | 2013-04-24 | — | — | EP | claimed |
| US-20110318741-A1 | BIOMARKERS FOR THE TREATMENT OF PSORIASIS | AMGEN INC. | 2011-12-29 | — | — | US | claimed |
| WO-2011159750-A1 | BIOMARKERS FOR THE TREATMENT OF PSORIASIS | CELGENE CORPORATION (US) | 2011-12-22 | — | — | WO | claimed |
| US-20080269123-A1 | Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases | STOWERS MEDICAL INSTITUTE INC. | 2008-10-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170231931-A1 | PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES | SNCA, PSEN2, PSEN1 | PDE4B 1380/4885PDE4C 1669/4885PDE4A 1415/4885 |
| US-10913717-B2 | Solid state forms of N-[2-[(I S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methyl sulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-L H-isoindol-4-yl]acetamide and process for preparation thereof | SULT1A1, SULT2A1, SULT1E1 | PDE4B 2424/4885PDE4C 2986/4885PDE4A 2312/4885 |
| US-20200345731-A1 | COMBINATION THERAPIES COMPRISING APREMILAST AND TYK2 INHIBITORS | PDE4A, TYK2, PDE4B | PDE4B 3/4885PDE4C 10/4885PDE4A 1/4885 |
| US-10919855-B2 | Process to prepare n-[2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulphonyl) ethyl]-1, 3-dioxo-2,3-dihydro-1h-isoindol-4yl]acetamide | DMPK, BCKDK, MYLK | PDE4B 905/4885PDE4C 1639/4885PDE4A 1215/4885 |
| US-11357775-B2 | Combination therapies comprising apremilast and Tyk2 inhibitors | PDE4A, TYK2, PDE4B | PDE4B 3/4885PDE4C 10/4885PDE4A 1/4885 |
| US-20220339151-A1 | COMBINATION THERAPIES COMPRISING APREMILAST AND TYK2 INHIBITORS | PDE4A, TYK2, PDE4B | PDE4B 3/4885PDE4C 10/4885PDE4A 1/4885 |
| US-20250235450-A1 | COMBINATION THERAPIES COMPRISING APREMILAST AND TYK2 INHIBITORS | PDE4A, TYK2, PDE4B | PDE4B 3/4885PDE4C 10/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.